2020
Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy
Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs 2020, 40: 42-52. PMID: 33211536, PMCID: PMC7931245, DOI: 10.1377/hlthaff.2020.02054.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineVaccine efficacyCoronavirus disease 2019 (COVID-19) vaccinesSignificant vaccine hesitancyClinical outcomesClinical trialsVaccination programVaccine hesitancyEpidemic severityVaccineAuthorized vaccinesHealth officialsCumulative infectionsEfficacyVaccine productionDistribution programSeverityOutcomesUrgent needHospitalizationVaccinationInfectionTrialsGlobal efforts
2019
Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study
Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. The Lancet Infectious Diseases 2019, 19: 728-739. PMID: 31130329, PMCID: PMC6595249, DOI: 10.1016/s1473-3099(18)30804-1.Peer-Reviewed Original ResearchConceptsGross domestic productWTP valuesCountry's gross domestic productOptimal strategyCountry-specific willingnessAverage net benefitHealth economic evaluationsGAVI-eligible countriesTyphoid ViPay valueDomestic productVaccine priceWTP thresholdEconomic evaluationVaccine-related costsNet benefitMiddle-income countriesGavi supportVaccine AllianceRoutine immunisationHospital admissionCountriesTCV introductionDALYsTransmission dynamic model
2016
Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa
Bilinski AM, Fitzpatrick MC, Rupprecht CE, Paltiel AD, Galvani AP. Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proceedings Of The Royal Society B 2016, 283: 20161211. PMID: 27852799, PMCID: PMC5124087, DOI: 10.1098/rspb.2016.1211.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDog DiseasesDogsHumansImmunization ProgramsRabiesRabies VaccinesRabies virusTanzaniaVaccinationConceptsVaccination campaignRabies vaccination campaignsOptimal vaccination strategyPublic health benefitsWorld Health OrganizationVaccination strategiesRabies vaccinationVirus transmission modelDisease reintroductionSub-Saharan AfricaHealth OrganizationHealth benefitsRabies reintroductionRabiesNorthwest TanzaniaHuman deathsPrevious studiesVaccinationYearsDisease
2014
A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”
Skene KJ, Paltiel AD, Shim E, Galvani AP. A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”. Medical Decision Making 2014, 34: 536-549. PMID: 24740238, PMCID: PMC4209160, DOI: 10.1177/0272989x14523502.Peer-Reviewed Original ResearchConceptsHerd immunity thresholdSeasonal influenza epidemicsVaccination coverageSeasonal influenzaVaccination strategiesEpidemiological findingsImmunity thresholdHerd immunityInfluenza epidemicsVaccination changesPotential superspreadersSimplified transmission modelVaccinationTarget populationIntervention designEpidemicInfluenzaInterventionTransmission model
2013
Dengue dynamics and vaccine cost-effectiveness in Brazil
Durham DP, Mbah M, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 2013, 31: 3957-3961. PMID: 23791696, PMCID: PMC3755607, DOI: 10.1016/j.vaccine.2013.06.036.Peer-Reviewed Original ResearchMeSH KeywordsBrazilCost-Benefit AnalysisDengueDengue VaccinesHumansImmunity, HerdImmunization ProgramsModels, EconomicModels, TheoreticalVaccinationConceptsVaccination costsDengue vaccine trialsVaccine efficacyTotal vaccination costDengue vaccinationCost-effectiveness analysisPotential vaccination policiesVaccine trialsPay thresholdsVaccine efficacy scenariosOptimal allocationLow vaccine efficacyLatest clinical trialsOptimistic scenarioTrial estimatesVaccination coverageEfficacy scenariosClinical trialsAvailable dosesVaccination policyFurther trialsVaccination modelHerd immunityVaccinationCost
2012
Impact of Program Scale and Indirect Effects on the Cost-Effectiveness of Vaccination Programs
Ibuka Y, Paltiel AD, Galvani AP. Impact of Program Scale and Indirect Effects on the Cost-Effectiveness of Vaccination Programs. Medical Decision Making 2012, 32: 442-446. PMID: 22472916, PMCID: PMC3570235, DOI: 10.1177/0272989x12441397.Peer-Reviewed Original Research
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccine